Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41392-021-00835-6 http://scihub22266oqcxt.onion/10.1038/s41392-021-00835-6 34873151!8646019!34873151     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\34873151.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Signal+Transduct+Target+Ther 2021 ; 6 (1): 414 Nephropedia Template TP {{tp|p=34873151|t=2021. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients |pdf=|usr=}}{{34873151}} gab.com Text Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients JO: Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=34873151 #FOAvip Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it into Phase III trial for COVID-19 patients. FNC monophosphate analog inhibited SARS-CoV-2 and HCoV-OC43 coronavirus with an EC(50) between 1.2 and 4.3 muM, depending on viruses or cells, and selective index (SI) in 15-83 range. Oral administration of FNC in rats revealed a substantial thymus-homing feature, with FNC triphosphate (the active form) concentrated in the thymus and peripheral blood mononuclear cells (PBMC). Treating SARS-CoV-2 infected rhesus macaques with FNC (0.07 mg/kg, qd, orally) reduced viral load, recuperated the thymus, improved lymphocyte profiles, alleviated inflammation and organ damage, and lessened ground-glass opacities in chest X-ray. Single-cell sequencing suggested the promotion of thymus function by FNC. A randomized, single-arm clinical trial of FNC on compassionate use (n = 31) showed that oral FNC (5 mg, qd) cured all COVID-19 patients, with 100% viral ribonucleic acid negative conversion in 3.29 +/- 2.22 days (range: 1-9 days) and 100% hospital discharge rate in 9.00 +/- 4.93 days (range: 2-25 days). The side-effect of FNC is minor and transient dizziness and nausea in 16.12% (5/31) patients. Thus, FNC might cure COVID-19 through its anti-SARS-CoV-2 activity concentrated in the thymus, followed by promoted immunity. Twit Text FOAVip Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients ????Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=34873151 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34873151 #FOAvip English Wikipedia <ref>{{Cite pmid|34873151}}</ref> Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients #MMPMID34873151 Zhang JL; Li YH; Wang LL; Liu HQ; Lu SY; Liu Y; Li K; Liu B; Li SY; Shao FM; Wang K; Sheng N; Li R; Cui JJ; Sun PC; Ma CX; Zhu B; Wang Z; Wan YH; Yu SS; Che Y; Wang CY; Wang C; Zhang Q; Zhao LM; Peng XZ; Cheng Z; Chang JB; Jiang JD Signal Transduct Target Ther 2021[Dec]; 6 (1): 414 PMID34873151show ga Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it into Phase III trial for COVID-19 patients. FNC monophosphate analog inhibited SARS-CoV-2 and HCoV-OC43 coronavirus with an EC(50) between 1.2 and 4.3 muM, depending on viruses or cells, and selective index (SI) in 15-83 range. Oral administration of FNC in rats revealed a substantial thymus-homing feature, with FNC triphosphate (the active form) concentrated in the thymus and peripheral blood mononuclear cells (PBMC). Treating SARS-CoV-2 infected rhesus macaques with FNC (0.07 mg/kg, qd, orally) reduced viral load, recuperated the thymus, improved lymphocyte profiles, alleviated inflammation and organ damage, and lessened ground-glass opacities in chest X-ray. Single-cell sequencing suggested the promotion of thymus function by FNC. A randomized, single-arm clinical trial of FNC on compassionate use (n = 31) showed that oral FNC (5 mg, qd) cured all COVID-19 patients, with 100% viral ribonucleic acid negative conversion in 3.29 +/- 2.22 days (range: 1-9 days) and 100% hospital discharge rate in 9.00 +/- 4.93 days (range: 2-25 days). The side-effect of FNC is minor and transient dizziness and nausea in 16.12% (5/31) patients. Thus, FNC might cure COVID-19 through its anti-SARS-CoV-2 activity concentrated in the thymus, followed by promoted immunity. |*COVID-19 Drug Treatment[MESH] |*Thymus Gland/metabolism/virology[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Animals[MESH] |Antiviral Agents/*administration & dosage[MESH] |Azides/*administration & dosage[MESH] |Coronavirus OC43, Human/metabolism[MESH] |Deoxycytidine/administration & dosage/*analogs & derivatives[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Rats[MESH]Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating(epmc).pdf DeepDyve Pubget Overpricing